Supplementary Figure S6 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance

<p>Supplementary Figure S6 demonstrates the specific activation of the Type I conventional DC (cDC1) subset by BCL2 inhibitors in different mouse orthotopic cancer models.</p>